Army 17.1 sbir phase II medical r & d contract for proposal #A2-7469, titled "development of a flexible, live tetravalent dengue vaccine" ERMS18263006
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH19C0051
- Awardee
-
Codagenix Inc. UEI TEMNL437K2F1
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $947,584
Award facts
- Opportunity
-
- HQ003418ROCAB Solicitation number
- Contract value 100% obligated
- $947,584.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AN91 R&D- Medical: Other (Basic Research)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 8 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Farmingdale, NY 11735, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $496,327 | |
| Original award | $451,257 |
About this award
The Department of the Army Medical Command awarded a $947,584.12 Small Business Innovation Research (SBIR) Phase II contract to Codagenix Inc., a clinical-stage biotechnology company, to develop a flexible, live tetravalent dengue vaccine. This definitive, firm-fixed-price contract has a completion date of June 14, 2023. Codagenix has also been awarded several other federal contracts and grants for the research, development, and clinical evaluation of viral vaccines, including a $389 million contract from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to conduct a Phase 2B efficacy study of Codagenix's Coviliv COVID-19 vaccine.
Quick answers
Who was awarded contract W81XWH19C0051?
W81XWH19C0051 was awarded to Codagenix Inc. by Medical Command (Department of the Army) on April 15, 2019.
How much is contract W81XWH19C0051 worth?
The government has obligated $947,584 on W81XWH19C0051.
Was contract W81XWH19C0051 competed?
The extent of competition for W81XWH19C0051 was full and open competition after exclusion of sources. The government received 8 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award